Percutaneous microwave ablation combined with synchronous transcatheter arterial chemoembolization for the treatment of colorectal liver metastases: results from a follow-up cohort
Authors Wu Z, Si Z, Qian S, Liu L, Qu X, Zhou B, Zhang W, Wang G, Liu R, Wang J
Received 27 January 2016
Accepted for publication 13 April 2016
Published 23 June 2016 Volume 2016:9 Pages 3783—3789
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Triparna Sen
Peer reviewer comments 3
Editor who approved publication: Professor Min Li
Zeng-Bao Wu,1,* Zeng-Mei Si,1,* Sheng Qian,1 Ling-Xiao Liu,1 Xu-Dong Qu,1 Bo Zhou,1 Wei Zhang,1 Guang-Zhi Wang,2 Rong Liu,1 Jian-Hua Wang1
1Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Department of Intervention Radiology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Background: The purpose of this study was to retrospectively evaluate the therapeutic efficacy and safety of ultrasound-guided percutaneous microwave ablation (MWA) combined with synchronous transcatheter arterial chemoembolization (TACE) in patients with colorectal liver metastases (CRLM).
Patients and methods: A retrospective analysis was performed in 30 patients who were treated with ultrasound-guided percutaneous MWA combined with synchronous TACE for colorectal cancer liver metastases from November 2011 to December 2014 in Zhongshan Hospital, Fudan University. The response of the tumor to treatment was evaluated by follow-up computed tomography and/or magnetic resonance imaging. Local tumor control, procedure-related complications, and long-term survival data were analyzed.
Results: A total of 30 patients with 43 tumors ranging in size from 1.4 cm to 10.0 cm were analyzed. The patients’ mean age was 61.6±10.3 years (range, 44.0–78.0 years). The median follow-up time was 26.5±10.4 months (range, 13.3–50.6 months). The complete ablation rate was 81.4% (35/43 lesions) for CRLM. Complete response was achieved in eight cases (26.7%), and partial response was achieved in 17 cases (56.7%) 1 month after the procedure. The objective response rate (complete response + partial response) was 83.4%. Progression-free survival and overall survival were 5.0 months and 11.0 months, respectively. The 12-month and 24-month survival rates were 46.7% and 25.4%, respectively. A total of 22 patients succumbed during follow-up due to tumor progression. No major complications or perioperative mortalities were recorded.
Conclusion: Ultrasound-guided percutaneous MWA combined with synchronous TACE therapy is a safe and effective modality for patients with CRLM.
Keywords: colorectal liver metastases, microwave ablation, transcatheter arterial chemoembolization
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]